Acadia Healthcare Executive Brian Farley Sells 1,770 Shares at $34.51

Executive's Open Market Share Sale at Acadia Healthcare

Brian Farley, who serves as Executive Vice President, Chief Legal and Administrative Officer and Secretary at Acadia Healthcare Company, Inc., executed an open market sale of common stock on July 26, 2026. According to the regulatory disclosure filed on July 27, 2026, Farley sold 1,770 shares at a transaction price of $34.51 per share. The sale reflects routine insider market activity by a senior executive of the Florida-based behavioral healthcare operator, which provides psychiatric and substance use disorder treatment services across the United States through inpatient and outpatient facilities.

Following the completion of this transaction, Farley's direct beneficial ownership position in Acadia Healthcare decreased to 135,982 common shares. The disclosure indicates that all 135,982 shares remaining in Farley's account are held in direct ownership form, with no indication of indirect beneficial ownership arrangements. This level of share ownership underscores Farley's continued financial alignment with the company's performance and shareholder interests.

Transaction Details and Ownership Impact

The transaction on July 26, 2026, involved the disposition of 1,770 shares through an open market sale, coded as a "F" transaction in regulatory filings—a standard designation for open market dispositions. The $34.51 per-share price represents the market price at which the shares traded at the time of the sale. The total proceeds from this transaction would have equated to approximately $61,081, though the filing does not explicitly disclose the aggregate sale proceeds.

The sale represents less than 1.3 percent of Farley's total direct beneficial ownership position. The remaining 135,982 shares indicate that Farley maintains a substantial stake in the company. As a senior executive responsible for legal and administrative functions, Farley's continued shareholding in Acadia Healthcare is consistent with typical executive compensation and benefit arrangements. The filing contains no indication of any restriction or limitation on future trading activity, nor does it suggest any special circumstances surrounding the sale.

Regulatory Disclosure and Filing Procedures

The transaction was disclosed through an SEC Form 4 filing, the standard regulatory document required under Section 16(a) of the Securities Exchange Act of 1934 for officers, directors, and significant shareholders of publicly traded companies. The form was signed by Farley on July 27, 2026, one business day after the transaction date of July 26, 2026. This timeline is consistent with standard SEC reporting requirements, which generally allow officers and executives to file beneficial ownership change reports within two business days of a transaction.

The filing identifies Farley's residence as 4020 Aspen Grove Drive, Suite 900, Franklin, Tennessee 37067, and confirms his title as Executive Vice President, Chief Legal and Administrative Officer and Secretary. The form explicitly notes that Farley is subject to Section 16 reporting obligations, indicating his status as a covered insider. No amendment to a prior filing was required, and the disclosure does not reference any contract, instruction, or written trading plan under Rule 10b5-1(c), suggesting this was a discretionary open market sale rather than part of a pre-arranged trading arrangement.

Acadia Healthcare's Executive Leadership and Insider Ownership

Brian Farley's position as Executive Vice President, Chief Legal and Administrative Officer and Secretary places him among Acadia Healthcare's senior management team. In this role, Farley is responsible for overseeing the company's legal affairs, regulatory compliance, and administrative operations—critical functions for a healthcare operator managing numerous facilities across multiple states and subject to extensive healthcare regulations. His beneficial ownership of 135,982 shares following this sale indicates a meaningful personal financial stake in the company's long-term value and performance.

The disclosure does not reveal whether other company insiders have engaged in trading activity around the same date, nor does it provide comparative information about historical trading patterns by Farley or other executives. Investors monitoring insider trading activity at Acadia Healthcare may observe trading disclosures as part of broader efforts to understand management confidence levels and capital allocation priorities at the company. Such trading activity is publicly available through SEC EDGAR filings and can be searched by interested parties on a real-time basis.

Market Context and Behavioral Healthcare Industry

Acadia Healthcare Company, Inc. operates as a leading provider of behavioral health and addiction treatment services in the United States. The company operates inpatient psychiatric facilities, residential treatment centers, and outpatient clinics serving patients with mental health conditions and substance use disorders. As of the date of this transaction, the company's common stock was trading in the market, and the $34.51 per-share price at which Farley's shares were sold reflects prevailing market conditions for ACHC equity on that date.

The behavioral healthcare sector has experienced significant industry dynamics in recent years, including increased demand for mental health services, evolving reimbursement models, and ongoing regulatory scrutiny of treatment facilities. Insiders' decisions to buy or sell shares can sometimes reflect their assessments of company prospects, though individual transactions by executives are influenced by numerous personal factors including portfolio diversification, tax planning, and liquidity needs, and should not be interpreted as commentary on company performance or outlook without additional context.

Filing Compliance and Documentation Requirements

The Form 4 filing meets standard SEC requirements for beneficial ownership reporting. The document provides a clear record of the transaction code, date, number of securities, price, and resulting beneficial ownership position. The filing states that the reporting person checked the box indicating "Form filed by One Reporting Person," confirming that this is a single-person disclosure rather than a joint or group filing. No check marks appear next to items indicating that Farley is no longer subject to Section 16 obligations or that the transaction was made pursuant to a Rule 10b5-1 trading plan.

The disclosure includes explicit certification language warning that intentional misstatements or omissions of facts in the form constitute federal criminal violations under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a). Farley signed the document on July 27, 2026, certifying the accuracy and completeness of the information provided. The SEC Form 4 filing is part of the public record and is available through the SEC's EDGAR database, accessible to investors, analysts, and other interested parties at no charge.

Investor Considerations and Ongoing Monitoring

Investors holding ACHC stock or considering an investment in Acadia Healthcare may wish to monitor insider trading disclosures as one element of their investment analysis and due diligence process. Patterns of insider buying or selling can provide signals about management sentiment regarding the company's value and prospects, though individual transactions should be evaluated within a broader context of company fundamentals, market conditions, and personal financial circumstances of insiders. The SEC requires all such transactions to be reported promptly and provides easy public access to this information through EDGAR filings.

The immediate share price impact of this particular transaction was not clear from available public information. The filing does not disclose any simultaneous market movements, analyst reactions, or trading volume changes associated with Farley's share sale. Investors interested in tracking insider activity at Acadia Healthcare can establish alerts through the SEC EDGAR system or use third-party financial data services that aggregate and analyze insider trading disclosures across publicly traded companies. Such monitoring may contribute to a more comprehensive understanding of company leadership's perspective on shareholder value creation.